Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 03 04:00PM ET
4.55
Dollar change
+0.35
Percentage change
8.20
%
Index- P/E- EPS (ttm)-2.65 Insider Own- Shs Outstand1.54M Perf Week12.62%
Market Cap7.01M Forward P/E- EPS next Y-0.66 Insider Trans0.00% Shs Float1.25M Perf Month10.98%
Income-4.08M PEG- EPS next Q-0.20 Inst Own3.16% Short Float0.67% Perf Quarter11.28%
Sales2.52M P/S2.78 EPS this Y-46.38% Inst Trans140.12% Short Ratio0.38 Perf Half Y12.27%
Book/sh4.56 P/B1.00 EPS next Y34.65% ROA-40.76% Short Interest0.01M Perf Year46.77%
Cash/sh4.44 P/C1.03 EPS next 5Y- ROE-45.48% 52W Range2.78 - 5.20 Perf YTD31.88%
Dividend Est.- P/FCF- EPS past 5Y51.08% ROI-57.94% 52W High-12.50% Beta2.24
Dividend TTM- Quick Ratio6.96 Sales past 5Y- Gross Margin- 52W Low63.67% ATR (14)0.35
Dividend Ex-Date- Current Ratio6.96 EPS Y/Y TTM- Oper. Margin-172.82% RSI (14)64.73 Volatility8.34% 9.14%
Employees4 Debt/Eq0.00 Sales Y/Y TTM7.15% Profit Margin-161.58% Recom3.00 Target Price40.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q58.88% Payout- Rel Volume1.81 Prev Close4.20
Sales Surprise-18.11% EPS Surprise-100.00% Sales Q/Q0.50% EarningsNov 13 BMO Avg Volume22.02K Price4.55
SMA2014.41% SMA5014.84% SMA20014.22% Trades Volume39,765 Change8.20%
Date Action Analyst Rating Change Price Target Change
Jan-08-20Initiated Maxim Group Buy $2.50
Nov-22-24 09:15AM
Nov-21-24 08:30AM
Nov-13-24 08:30AM
Nov-12-24 09:00AM
Nov-07-24 09:00AM
08:45AM Loading…
Oct-22-24 08:45AM
Oct-17-24 08:45AM
Sep-11-24 09:00AM
Aug-14-24 08:00AM
Aug-13-24 10:54PM
May-22-24 05:00PM
May-10-24 08:30AM
May-09-24 11:55PM
08:00PM
Mar-22-24 08:00AM
07:53AM Loading…
07:53AM
Jan-17-24 09:00AM
Nov-10-23 08:43AM
08:35AM
Oct-18-23 10:00AM
Oct-11-23 09:05AM
Sep-05-23 08:05AM
Aug-11-23 09:25AM
08:24AM
08:05AM
Aug-10-23 05:30PM
Jul-13-23 12:00PM
Jul-05-23 08:45AM
May-15-23 08:08AM
May-12-23 12:30PM
04:42PM Loading…
May-11-23 04:42PM
04:30PM
May-04-23 08:35AM
May-03-23 08:35AM
Apr-11-23 08:30AM
Mar-23-23 07:35AM
Mar-16-23 08:05AM
Jan-17-23 08:05AM
Jan-11-23 01:00PM
Jan-05-23 08:05AM
Dec-15-22 06:05AM
Dec-01-22 05:47AM
Nov-16-22 08:35AM
Nov-12-22 08:04AM
Nov-10-22 07:05AM
Oct-11-22 08:05AM
Oct-04-22 08:00AM
Sep-07-22 08:05AM
Aug-12-22 08:00AM
Aug-02-22 08:05AM
Jul-07-22 09:00AM
Jun-02-22 02:00PM
08:35AM
May-18-22 08:15AM
May-12-22 04:05PM
Apr-27-22 06:30AM
Mar-23-22 08:30AM
Jan-12-22 10:35AM
Nov-12-21 08:00AM
Nov-04-21 03:01PM
Sep-09-21 08:05AM
Sep-08-21 08:00AM
Aug-13-21 08:05AM
Jul-30-21 11:30AM
Jul-28-21 02:00PM
Jul-27-21 08:27AM
Jul-26-21 07:00AM
May-12-21 07:00AM
May-10-21 08:30AM
Mar-29-21 08:05AM
Mar-17-21 08:00AM
Mar-03-21 08:05AM
Mar-01-21 09:49AM
Feb-16-21 07:30AM
Feb-01-21 09:47AM
Jan-14-21 08:00AM
Jan-05-21 08:05AM
Dec-14-20 11:15AM
Dec-10-20 07:42AM
12:50AM
Dec-09-20 11:35AM
08:35AM
Nov-13-20 08:00AM
Nov-05-20 08:05AM
Sep-09-20 08:35AM
Sep-08-20 09:34AM
Aug-13-20 07:05AM
Jul-30-20 08:05AM
Jul-01-20 08:05AM
Jun-16-20 08:05AM
Jun-08-20 08:35AM
May-19-20 07:35AM
May-14-20 04:05PM
Apr-15-20 08:35AM
Mar-27-20 09:00AM
Feb-27-20 08:00AM
Feb-26-20 08:00AM
Feb-13-20 08:00AM
Feb-11-20 08:05AM
Jan-14-20 08:35AM
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.